financetom
Business
financetom
/
Business
/
Revvity's Q2 Adjusted Earnings Rise, Revenue Falls; Raises Full-Year Earnings Guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Revvity's Q2 Adjusted Earnings Rise, Revenue Falls; Raises Full-Year Earnings Guidance
Jul 29, 2024 4:09 AM

06:53 AM EDT, 07/29/2024 (MT Newswires) -- Revvity ( RVTY ) reported Q2 adjusted earnings Monday of $1.22 per diluted share, up from $1.21 a year earlier.

Analysts polled by Capital IQ expected $1.12.

Revenue for the quarter ended June 30 was $691.7 million, compared with $709.1 million a year earlier.

Analysts surveyed by Capital IQ expected $689.2 million.

The company raised its full-year 2024 adjusted earnings guidance to $4.70 to $4.80 per diluted share, from $4.55 to $4.75. Analysts polled by Capital IQ expect $4.63.

The company narrowed its revenue outlook for the year to $2.77 billion to $2.79 billion, from $2.76 billion to $2.82 billion. Analysts surveyed by Capital IQ expect $2.79 billion.

Revvity ( RVTY ) shares rose 6% in premarket trading.

Price: 122.90, Change: +7.75, Percent Change: +6.73

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Africa Energy Enters Non-Binding Agreement With Arostyle
Africa Energy Enters Non-Binding Agreement With Arostyle
Dec 20, 2024
07:10 AM EST, 12/20/2024 (MT Newswires) -- Africa Energy ( HPMCF ) on Friday entered into a non-binding agreement with Arostyle Investments to restructure their joint investment in Main Street 1549 Proprietary, which currently has a direct 10% participating interest in Block 11B / 12B offshore South Africa. The company said in light of the withdrawal of the joint venture...
Novo Nordisk to explore CagriSema weight-loss potential in new trial
Novo Nordisk to explore CagriSema weight-loss potential in new trial
Dec 20, 2024
COPENHAGEN, Dec 20 (Reuters) - Novo Nordisk will begin a new trial to explore further weight-loss potential of its experimental CagriSema drug in the first half of 2025, the company said on Friday, after posting disappointing data for the drug candidate. We plan to optimize dose titration to further explore CagriSema's additional weight loss potential with a new trial planned...
OpenAI to appeal against Italy's privacy watchdog decision
OpenAI to appeal against Italy's privacy watchdog decision
Dec 20, 2024
MILAN, Dec 20 (Reuters) - ChatGPT maker OpenAI said on Friday it would appeal against a decision by Italy's privacy watchdog, which it called disproportionate. The authority fined on Friday OpenAI 15 million euros ($15.58 million) after closing an investigation into use of personal data by the generative artificial intelligence application. ...
Zealand Pharma CEO says Novo's CagriSema data supports monotherapy approach to cagrilintide
Zealand Pharma CEO says Novo's CagriSema data supports monotherapy approach to cagrilintide
Dec 20, 2024
COPENHAGEN, Dec 20 (Reuters) - The CEO of Danish drugmaker Zealand Pharma said on Friday that the data from Novo Nordisk's CagriSema study supported Zealand's own monotherapy approach to cagrilintide. The data supports our monotherapy approach to cagrilintide big time, even though CagriSema may have disappointed the market, Zealand Pharma CEO Adam Steensberg told Reuters after Novo Nordisk released its...
Copyright 2023-2026 - www.financetom.com All Rights Reserved